Clinical trials: Recurrent NSCLC
Adenocarcinoma of the Lung, Large Cell Lung Cancer
Photodynamic Therapy in Treating Patients With Lung Cancer
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT01668823
- Testing
- HPPH, photodynamic therapy, therapeutic bronchoscopy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This randomized phase II trial is studying carboplatin, paclitaxel, and vorinostat to see how well they work compared with carboplatin, paclitaxel, and a placebo in treating patients with stage III or stage IV non-small cell lung…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00481078
- Testing
- vorinostat, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897533
- Testing
- gene mapping, polymorphism analysis, diagnostic laboratory biomarker analysis
- Volunteers
- 137 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lung Cancer
Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Gold sodium thiomalate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of gold sodium thiomalate in…
- Trial name
- NCT00575393
- Testing
- gold sodium thiomalate, gene expression analysis, fluorine F 18 fluorothymidine
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Lung Cancer
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, gemcitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079287
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 24 sites in Japan
- Sponsor
- Japan Multinational Trial Organization
Lung Cancer
Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00519831
- Testing
- cetuximab, vinflunine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer, Lung Cancer
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
RATIONALE: A disease management program may be more effective than standard therapy in improving quality of life and controlling symptoms in patients with cancer.
- Conditions
- Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00684801
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- United States
- Volunteers
- 605 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00014430
- Testing
- trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal…
- Trial name
- NCT02438722
- Testing
- Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
- Where
- 638 sites in United States
- Volunteers
- 174 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Celecoxib may slow the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00068653
- Testing
- Celecoxib, ZD1839
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00278460
- Testing
- docetaxel, gemcitabine hydrochloride
- Volunteers
- 49 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077246
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00354549
- Testing
- bevacizumab + erlotinib hydrochloride, gemcitabine hydrochloride + cisplatin or carboplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 104 people
- Sponsor
- Swiss Cancer Institute
HER2-positive Breast Cancer, Recurrent Breast Cancer
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
This phase I trial studies the safety and the ability to expand laboratory-treated T cells when given together with cyclophosphamide or denileukin diftitox in treating patients with human epidermal growth factor receptor…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00228358
- Testing
- ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Carcinoma, Non-Small-Cell Lung Carcinoma
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
- Conditions
- Carcinoma, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms
- Trial name
- NCT00243347
- Testing
- AZD2171
- Where
- 2 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV.
- Trial name
- NCT02178163
- Testing
- cytology specimen collection procedure, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 619 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer, Metastatic Cancer
Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Heating paclitaxel to several degrees above body temperature and infusing it to the affected area around the…
- Trial name
- NCT00020007
- Testing
- isolated perfusion, paclitaxel, hyperthermia treatment
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
- Trial name
- NCT06962865
- Testing
- RC108, Furmonertinib Mesilate Tablets Monotherapy
- Where
- 34 sites in China
- Volunteers
- 80 people
- Sponsor
- RemeGen Co., Ltd.
Lung Cancer
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064012
- Testing
- bortezomib, docetaxel
- Where
- 21 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison